After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs
July 12, 2011
Dirksen Senate Office Building, Health, Education, Labor & Pensions Committee Room, SD-430
1st and C Streets, NE
Washington, DC 20510
The Pew Health Group will host a Capitol Hill forum on the release of a white paper, After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs, on Tuesday, July 12. The event is an opportunity to take an in-depth look at the risks associated with an increasingly complex, globalized and outsourced pharmaceutical supply chain and ways policy makers can make medicine supply our safer for patients.
Allan Coukell, a pharmacist and director of Medical Programs at the Pew Health Group, will moderate a panel discussion. The invited panelists are policy makers and pharmaceutical industry leaders in manufacturing and distribution:
- Pew Representatives
- Allan Coukell, deputy director of Medical Programs (moderator)
- Gabey Cosel, project manager of the of the Pew Prescription Project
- Policy makers
- Deborah M. Autor, Esq., director, Office of Compliance, Center for Drug Evaluation and Research
- Business Leaders
- Heather Bresch, president, Mylan
- John Gray, president and CEO, Healthcare Distribution Management Association (HDMA)
Time: 11:00-12:30 a.m. Doors open at 10:30 a.m.
Box lunches available immediately following the panel discussion.
Please email Yasmeen Husain at email@example.com by Monday, July 11 to RSVP.